Alcohol, psoriasis, liver disease, and anti-psoriasis drugs

International Journal of Dermatology

Volumn 50, Issue 11, 2011, Pages 1323-1331

  Cassano, Nicoletta ^a   Vestita, Michelangelo ^a   Apruzzi, Doriana ^a   Vena, Gino A ^a  

^a UNIVERSITY OF BARI   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ACETALDEHYDE; ACETONE; ADALIMUMAB; ALCOHOL; ANTIPSORIASIS AGENT; AZATHIOPRINE; CYCLOSPORIN A; ETANERCEPT; ETRETIN; INFLIXIMAB; METHOTREXATE; MONOCLONAL ANTIBODY; NONSTEROID ANTIINFLAMMATORY AGENT; PREDNISONE; RETINOID DERIVATIVE; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ANTIBODY;

ALCOHOL ABUSE; ALCOHOL CONSUMPTION; ALCOHOL LIVER DISEASE; AUTOIMMUNE HEPATITIS; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISEASE ASSOCIATION; DISEASE PREDISPOSITION; DISEASE SEVERITY; DRUG ALCOHOL INTERACTION; DRUG CONTRAINDICATION; DRUG SURVEILLANCE PROGRAM; DRUG TREATMENT FAILURE; FOLIC ACID DEFICIENCY; HEPATITIS; HUMAN; IMMUNE DYSREGULATION; INFECTION; JAUNDICE; LIVER DISEASE; LIVER DYSFUNCTION; LIVER FAILURE; LIVER FIBROSIS; LIVER INJURY; LIVER TOXICITY; LOW DRUG DOSE; NONALCOHOLIC FATTY LIVER; NONHUMAN; PATHOGENESIS; PREDICTION; PROGNOSIS; PSORIASIS; PSORIATIC ARTHRITIS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REM SLEEP; REVIEW; RHEUMATOID ARTHRITIS; RISK FACTOR; SEX DIFFERENCE; SIDE EFFECT; SINGLE DRUG DOSE; SLEEP DISORDER; STEATOHEPATITIS; STEATOSIS; TERATOGENESIS; TREATMENT OUTCOME;

ALCOHOL DRINKING; ALCOHOLISM; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIBODIES, MONOCLONAL; ETHANOL; HUMANS; LIVER DISEASES; PSORIASIS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 80054780486     PISSN: 00119059     EISSN: 13654632     Source Type: Journal    
DOI: 10.1111/j.1365-4632.2011.05100.x     Document Type: Review

References (92)

1. Delaney TJ, Leppard B. Alcohol intake and psoriasis. Acta Derm Venereol 1974; 54: 237-238.
2. Kavli G, Førde OH, Arnesen E, et al. Psoriasis: familial predisposition and environmental factors. Br Med J (Clin Res Ed) 1985; 291: 999-1000.
3. Monk BE, Neill SM. Alcohol consumption and psoriasis. Dermatologica 1986; 173: 57-60.
4. Vincenti GE, Blunden SM. Psoriasis and alcohol abuse. J R Army Med Corps 1987; 133: 77-78.
5. Lindegård B. Diseases associated with psoriasis in a general population of 159, 200 middle-aged, urban, native Swedes. Dermatologica 1986; 172: 298-304.
6. Braathen LR, Botten G, Bjerkedal T. Psoriatics in Norway. A questionnaire study on health status, contact with paramedical professions, and alcohol and tobacco consumption. Acta Derm Venereol Suppl 1989; 142: 9-12.
7. Wolf R, Wolf D, Ruocco V. Alcohol intake and psoriasis. Clin Dermatol 1999; 17: 423-430.
8. Higgins E. Alcohol, smoking and psoriasis. Clin Exp Dermatol 2000; 25: 107-110.
9. Poikolainen K, Reunala T, Karvonen J, et al. Alcohol intake: a risk factor for psoriasis in young and middle aged men? BMJ 1990; 300: 780-783.
10. Poikolainen K, Reunala T, Karvonen J. Smoking, alcohol and life events related to psoriasis among women. Br J Dermatol 1994; 130: 473-477.
11. Higgins EM, Peters TJ, du Vivier AW. Smoking, drinking and psoriasis. Br J Dermatol 1993; 129: 749-750.
12. Naldi L, Peli L, Parazzini F. Association of early-stage psoriasis with smoking and male alcohol consumption: evidence from an Italian case-control study. Arch Dermatol 1999; 135: 1479-1484.
13. Higgins EM, du Vivier AW. Alcohol and the skin. Alcohol Alcohol 1992; 27: 595-602.
14. Knopf B, Geyer A, Roth H, et al. Der Einfluss endogener und exogener Faktoren auf die Psoriasis vulgaris. Eine klinische Studie. Dermatol Monatsschr 1989; 175: 242-246.
15. Higgins EM, du Vivier AW. Cutaneous disease and alcohol misuse. Br Med Bull 1994; 50: 85-98.
16. Gupta MA, Schork NJ, Gupta AK, et al. Alcohol intake and treatment responsiveness of psoriasis: a prospective study. J Am Acad Dermatol 1993; 28: 730-732.
17. Higgins EM, du Vivier AW. Alcohol abuse and treatment resistance in skin disease. J Am Acad Dermatol 1994; 30: 1048.
18. Poikolainen K, Karvonen J, Pukkala E. Excess mortality related to alcohol and smoking among hospital-treated patients with psoriasis. Arch Dermatol 1999; 135: 1490-1493.
19. Hayes J, Koo J. Psoriasis: depression, anxiety, smoking, and drinking habits. Dermatol Ther 2010; 23: 174-180.
20. Griffiths CE, Richards HL. Psychological influences in psoriasis. Clin Exp Dermatol 2001; 26: 338-342.
21. Rapp SR, Feldman SR, Exum ML, et al. Psoriasis causes as much disability as other major medical diseases. J Am Acad Dermatol 1999; 41: 401-407.
22. Kirby B, Richards HL, Mason DL, et al. Alcohol consumption and psychological distress in patients with psoriasis. Br J Dermatol 2008; 158: 138-140.
23. Altobelli E, Petrocelli R, Maccarone M, et al. Risk factors of hypertension, diabetes and obesity in Italian psoriasis patients: a survey on socio-demographic characteristics, smoking habits and alcohol consumption. Eur J Dermatol 2009; 19: 252-256.
24. Baker RC, Jerrells TR. Recent developments in alcoholism: immunological aspects. Recent Dev Alcohol 1993; 11: 249-271.
25. Jareo PW, Preheim LC, Gentry MJ. Ethanol ingestion impairs neutrophil bactericidal mechanisms against Streptococcus pneumoniae. Alcohol Clin Exp Res 1996; 20: 1646-1652.
26. Liu YK. Effects of alcohol on granulocytes and lymphocytes. Semin Hematol 1980; 17: 130-136.
27. Imperia PS, Chikkappa G, Phillips PG. Mechanism of inhibition of granulopoiesis by ethanol. Proc Soc Exp Biol Med 1984; 175: 219-225.
28. MacGregor RR. Alcohol and immune defense. JAMA 1986; 256: 1474-1479.
29. Prinz JC. Bedeutung von Streptokokken fur die Psoriasispathogenese. Hautarzt 2009; 60: 109-115.
30. Waldschmidt TJ, Cook RT, Kovacs EJ. Alcohol and inflammation and immune responses: summary of the 2006 Alcohol and Immunology Research Interest Group (AIRIG) meeting. Alcohol 2008; 42: 137-142.
31. Szabo G, Mandrekar P. A recent perspective on alcohol, immunity, and host defense. Alcohol Clin Exp Res 2009; 33: 220-232.
32. Brion DE, Raynaud F, Plet A, et al. Deficiency of cyclic AMP-dependent protein kinases in human psoriasis. Proc Natl Acad Sci U S A 1986; 83: 5272-5276.
33. Fisher GJ, Tavakkol A, Leach K, et al. Differential expression of protein kinase C isoenzymes in normal and psoriatic adult human skin: reduced expression of protein kinase C-beta II in psoriasis. J Invest Dermatol 1993; 101: 553-559.
34. Tournier S, Gerbaud P, Anderson WB, et al. Post-translational abnormality of the type II cyclic AMP-dependent protein kinase in psoriasis: modulation by retinoic acid. J Cell Biochem 1995; 57: 647-654.
35. Voorhees JJ. "Psoriasis as a possible defect of the adenyl cyclase-cyclic AMP cascade" by Voorhees and Duell, October 1971. Commentary: cyclic adenosine monophosphate regulation of normal and psoriatic epidermis. Arch Dermatol 1982; 118: 862-874.
36. Ockenfels HM, Keim-Maas C, Funk R, et al. Ethanol enhances the IFN-gamma, TGF-alpha and IL-6 secretion in psoriatic co-cultures. Br J Dermatol 1996; 135: 746-751.
37. McClain CJ, Barve S, Deaciuc I, et al. Cytokines in alcoholic liver disease. Semin Liver Dis 1999; 19: 205-219.
38. Crews FT, Bechara R, Brown LA, et al. Cytokines and alcohol. Alcohol Clin Exp Res 2006; 30: 720-730.
39. Kawaguchi M, Mitsuhashi Y, Kondo S. Overexpression of tumour necrosis factor-alpha-converting enzyme in psoriasis. Br J Dermatol 2005; 152: 915-919.
40. Serwin AB, Sokolowska M, Dylejko E, et al. Tumour necrosis factor (TNF-alpha) alpha converting enzyme and soluble TNF-alpha receptor type 1 in psoriasis patients in relation to the chronic alcohol consumption. J Eur Acad Dermatol Venereol 2008; 22: 712-717.
41. Feingold KR, Man MQ, Menon GK, et al. Cholesterol synthesis is required for cutaneous barrier function in mice. J Clin Invest 1990; 86: 1738-1745.
42. Williams ML. Epidermal lipids and scaling diseases of the skin. Semin Dermatol 1992; 11: 169-175.
43. Sessa A, Tunici P, Perilli E, et al. Transglutaminase activity in rat liver after acute ethanol administration. Biochim Biophys Acta 1995; 1245: 371-375.
44. Wolf R, Lo Schiavo A, Lombardi ML, et al. The in vitro effect of hydroxychloroquine on skin morphology and transglutaminase. Int J Dermatol 1997; 36: 704-707.
45. Farkas A, Kemény L. Psoriasis and alcohol: is cutaneous ethanol one of the missing links? Br J Dermatol 2010; 162: 711-716.
46. Farkas A, Kemény L. The alcohol metabolite acetaldehyde and psoriasis: another trigger factor? Clin Exp Dermatol 2010; 35: 923-925.
47. Timmons SR, Nwankwo JO, Domann FE. Acetaldehyde activates Jun/AP-1 expression and DNA binding activity in human oral keratinocytes. Oral Oncol 2002; 38: 281-290.
48. Young CN, Koepke JI, Terlecky LJ, et al. Reactive oxygen species in tumor necrosis factor-alpha-activated primary human keratinocytes: implications for psoriasis and inflammatory skin disease. J Invest Dermatol 2008; 128: 2606-2614.
49. Gelernter J, Kranzler HR. Genetics of alcohol dependence. Hum Genet 2009; 126: 91-99.
50. Zachariae H, Sogaard H. Liver biopsy in psoriasis. A controlled study. Dermatologica 1973; 146: 149-155.
51. Chaput JC, Poynard T, Naveau S, et al. Psoriasis, alcohol, and liver disease. Br Med J (Clin Res Ed) 1985; 291: 25.
52. Tobin AM, Higgins EM, Norris S, et al. Prevalence of psoriasis in patients with alcoholic liver disease. Clin Exp Dermatol 2009; 34: 698-701.
53. Miele L, Vallone S, Cefalo C, et al. Prevalence, characteristics and severity of non-alcoholic fatty liver disease in patients with chronic plaque psoriasis. J Hepatol 2009; 51: 778-786.
54. Gisondi P, Targher G, Zoppini G, et al. Non-alcoholic fatty liver disease in patients with chronic plaque psoriasis. J Hepatol 2009; 51: 758-764.
55. Koca SS, Bahcecioglu IH, Poyrazoglu OK, et al. The treatment with antibody of TNF-alpha reduces the inflammation, necrosis and fibrosis in the non-alcoholic steatohepatitis induced by methionine- and choline-deficient diet. Inflammation 2008; 31: 91-98.
56. Barbuio R, Milanski M, Bertolo MB, et al. Infliximab reverses steatosis and improves insulin signal transduction in liver of rats fed a high-fat diet. J Endocrinol 2007; 194: 539-550.
57. Schramm C, Schneider A, Marx A, et al. Adalimumab could suppress the activity of non alcoholic steatohepatitis (NASH). Z Gastroenterol 2008; 46: 1369-1371.
58. Tilling L, Townsend S, David J. Methotrexate and hepatic toxicity in rheumatoid arthritis and psoriatic arthritis. Clin Drug Investig 2006; 26: 55-62.
59. Rosenberg P, Urwitz H, Johannesson A, et al. Psoriasis patients with diabetes type 2 are at high risk of developing liver fibrosis during methotrexate treatment. J Hepatol 2007; 46: 1111-1118.
60. Taylor WJ, Korendowych E, Nash P, et al. Drug use and toxicity in psoriatic disease: focus on methotrexate. J Rheumatol 2008; 35: 1454-1457.
61. Larsen FG, Jakobsen P, Knudsen J, et al. Conversion of acitretin to etretinate in psoriatic patients is influenced by ethanol. J Invest Dermatol 1993; 100: 623-627.
62. Zachariae H. Dangers of methotrexate/etretinate combination therapy. Lancet 1988; 1: 422.
63. Dominique L. Liver toxicity of TNF-alpha antagonists. Joint Bone Spine 2008; 75: 636-638.
64. European Medicines Agency. Infliximab Product Information. European Medicines Agency, 2010. (accessed June 30, 2011).
65. European Medicines Agency. Adalimumab Product Information. European Medicines Agency, 2010. (accessed June 30, 2011).
66. European Medicines Agency. Etanercept Product Information. European Medicines Agency, 2010. (accessed June 30, 2011).
67. Massarotti M, Marasini B. Successful treatment with etanercept of a patient with psoriatic arthritis after adalimumab-related hepatotoxicity. Int J Immunopathol Pharmacol 2009; 22: 547-549.
68. García Aparicio AM, Rey JR, Sanz AH, et al. Successful treatment with etanercept in a patient with hepatotoxicity closely related to infliximab. Clin Rheumatol 2007; 26: 811-813.
69. Becker H, Willeke P, Domschke W, et al. Etanercept tolerance in a patient with previous infliximab-induced hepatitis. Clin Rheumatol 2008; 27: 1597-1598.
70. Carlsen KM, Riis L, Madsen OR. Toxic hepatitis induced by infliximab in a patient with rheumatoid arthritis with no relapse after switching to etanercept. Clin Rheumatol 2009; 28: 1001-1003.
71. Bird GL, Sheron N, Goka AK, et al. Increased plasma tumor necrosis factor in severe alcoholic hepatitis. Ann Intern Med 1990; 112: 917-920.
72. Yin M, Gäbele E, Wheeler MD, et al. Alcohol-induced free radicals in mice: direct toxicants or signaling molecules? Hepatology 2001; 34: 935-942.
73. Yin M, Wheeler MD, Kono H, et al. Essential role of tumor necrosis factor alpha in alcohol-induced liver injury in mice. Gastroenterology 1999; 117: 942-952.
74. Neuman MG, Shear NH, Bellentani S, et al. Role of cytokines in ethanol-induced cytotoxicity in vitro in Hep G2 cells. Gastroenterology 1998; 115: 157-166.
75. Román J, Colell A, Blasco C, et al. Differential role of ethanol and acetaldehyde in the induction of oxidative stress in HEP G2 cells: effect on transcription factors AP-1 and NF-kappaB. Hepatology 1999; 30: 1473-1480.
76. Zhou Z, Sun X, Kang YJ. Ethanol-induced apoptosis in mouse liver: Fas- and cytochrome c-mediated caspase-3 activation pathway. Am J Pathol 2001; 159: 329-338.
77. Minagawa M, Deng Q, Liu ZX, et al. Activated natural killer T cells induce liver injury by Fas and tumor necrosis factor-alpha during alcohol consumption. Gastroenterology 2004; 126: 1387-1399.
78. Krueger JM, Toth LA. Cytokines as regulators of sleep. Ann N Y Acad Sci 1994; 739: 299-310.
79. Irwin M, Miller C, Gillin JC, et al. Polysomnographic and spectral sleep EEG in primary alcoholics: an interaction between alcohol dependence and African-American ethnicity. Alcohol Clin Exp Res 2000; 24: 1376-1384.
80. Irwin M, Gillin JC, Dang J, et al. Sleep deprivation as a probe of homeostatic sleep regulation in primary alcoholics. Biol Psychiatry 2002; 51: 632-641.
81. Redwine L, Dang J, Hall M, et al. Disordered sleep, nocturnal cytokines, and immunity in alcoholics. Psychosom Med 2003; 65: 75-85.
82. Irwin MR, Olmstead R, Valladares EM, et al. Tumor necrosis factor antagonism normalizes rapid eye movement sleep in alcohol dependence. Biol Psychiatry 2009; 66: 191-195.
83. Mookerjee RP, Sen S, Davies NA, et al. Tumour necrosis factor alpha is an important mediator of portal and systemic haemodynamic derangements in alcoholic hepatitis. Gut 2003; 52: 1182-1187.
84. Menon KV, Stadheim L, Kamath PS, et al. A pilot study of the safety and tolerability of etanercept in patients with alcoholic hepatitis. Am J Gastroenterol 2004; 99: 255-260.
85. Boetticher NC, Peine CJ, Kwo P, et al. A randomized, double-blinded, placebo-controlled multicenter trial of etanercept in the treatment of alcoholic hepatitis. Gastroenterology 2008; 135: 1953-1960.
86. Spahr L, Rubbia-Brandt L, Frossard JL, et al. Combination of steroids with infliximab or placebo in severe alcoholic hepatitis: a randomized controlled pilot study. J Hepatol 2002; 37: 448-455.
87. Tilg H, Jalan R, Kaser A, et al. Anti-tumor necrosis factor-alpha monoclonal antibody therapy in severe alcoholic hepatitis. J Hepatol 2003; 38: 419-425.
88. Sharma P, Kumar A, Sharma BC, et al. Infliximab monotherapy for severe alcoholic hepatitis and predictors of survival: an open label trial. J Hepatol 2009; 50: 584-591.
89. Naveau S, Chollet-Martin S, Dharancy S, et al. A double-blind randomized controlled trial of infliximab associated with prednisolone in acute alcoholic hepatitis. Hepatology 2004; 39: 1390-1397.
90. Poynard T, Thabut D, Chryssostalis A, et al. Anti-tumor necrosis factor-alpha therapy in severe alcoholic hepatitis: are large randomized trials still possible? J Hepatol 2003; 38: 518-520.
91. Blendis L, Dotan I. Anti-TNF therapy for severe acute alcoholic hepatitis: what went wrong? Gastroenterology 2004; 127: 1637-1639.
92. Mookerjee RP, Tilg H, Williams R, et al. Infliximab and alcoholic hepatitis. Hepatology 2004; 40: 499-500.